1/C26H18O2/c1-17-16-23-21-9-5-3-7-19(21)11-13-25(23)28-26(17)15-14-22-20-8-4-2-6-18(20)10-12-24(22)27-26/h2-16H,1H
1/C21H26N2O4/c1-3-14-8-9-19(25)23(12-14)11-10-16-15-6-4-5-7-18(15)22-20(16)17(13-24)21(26)27-2/h4-7,12,17,22,24H,3,8-11,13H2,1-2H
1/C17H22N6/c1-2-8-19-13-11-14(23-10-9-18-12-23)20-16-15(13)21-17(22-16)6-4-3-5-7-17/h9-12,19H,2-8H2,1H
1/C27H27N3O3S/c1-30-25(20-11-15-23(33-3)16-12-20)24(19-9-13-22(32-2)14-10-19)29-27(30)34-18-17-28-26(31)21-7-5-4-6-8-21/h4-16H,17-18H2,1-3H3,(H,28,31
1/C19H15ClN2O2S/c1-11-19(23)24-17-18(25-11)22(2)15-9-8-13(20)10-14(15)16(21-17)12-6-4-3-5-7-12/h3-11H,1-2H
1/C33H42O7/c1-19-25-17-24-18-27(39-22(4)35)20(2)29(32(24,5)6)30(37)31(33(25,7)16-15-26(19)38-21(3)34)40-28(36)14-13-23-11-9-8-10-12-23/h8-14,24-27,30-31,37H,1,15-18H2,2-7H3/b14-13+/t24-,25-,26+,27+,30-,31+,33-/m1/s
1/C18H18O6/c1-22-14-8-13(20)15-16(21)11(9-24-18(15)17(14)23-2)7-10-3-5-12(19)6-4-10/h3-6,8,11,19-20H,7,9H2,1-2H
1/C30H52/c1-10-25(6)16-12-20-30(9,21-13-17-26(7)15-11-14-23(2)3)29-22-27(8)18-19-28(29)24(4)5/h10,17,22-23,25,28-29H,1,4,11-16,18-21H2,2-3,5-9H3/b26-17
1/C28H41N5O15S.Na/c1-12(2)21(28(42)43)33-26(41)17(9-15-5-7-16(8-6-15)48-49(44,45)46)31-25(40)18(29-13(3)35)10-20(37)32-27-22(30-14(4)36)24(39)23(38)19(11-34)47-27;/h5-8,12,17-19,21-24,27,34,38-39H,9-11H2,1-4H3,(H,29,35)(H,30,36)(H,31,40)(H,32,37)(H,33,41
1/C23H22N2O2/c26-23(27-22-15-25-11-7-17(22)8-12-25)21-14-18(13-16-5-9-24-10-6-16)19-3-1-2-4-20(19)21/h1-6,9-10,13-14,17,22H,7-8,11-12,15H2/b18-13
1/C22H28O6/c1-23-17-11-21(27-5)19(25-3)9-15(17)13-7-8-14(13)16-10-20(26-4)22(28-6)12-18(16)24-2/h9-14H,7-8H2,1-6H3/t13-,14
1/C22H28O6/c1-23-17-11-21(27-5)19(25-3)9-15(17)13-7-8-14(13)16-10-20(26-4)22(28-6)12-18(16)24-2/h9-14H,7-8H2,1-6H3/t13-,14Share this page:
2-(7-Azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate [-5]
List of Suppliers
& after selecting multiple suppliers.
chemBlink suggests selecting .
& & &+86 (512)
& & &Chemical manufacturer since 2003
& & &chemBlink
since 2008
More Suppliers...
Identification
2-(7-Azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
TATU; O-(7-Azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluroni 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide tetrafluoroborate
Molecular Structure
Molecular Formula
C10H15N6O.BF4
Molecular Weight
CAS Registry Number
Safety Data
Market Analysis Reports
& & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & &
©& chemBlink. All rights reserved.Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty... - Abstract - Europe PMC
Europe PMC requires Javascript to function effectively.
Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please
turn on Javascript support in your web browser and reload this page.
Search worldwide, life-sciences literature
(PMID:8522681)
Holmes DR Jr
O'Hanesian MA
Schwartz RS
Serruys PW
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA.
Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Comparative Study
10.97(95)00439-4
OBJECTIVES: This study sought to compare the frequency of restenosis, reocclusion and adverse cardiovascular events after angioplasty of occluded versus nonoccluded coronary arteries. BACKGROUND: Angioplasty of chronically occluded coronary arteries is believed to be associated with a higher frequency of restenosis and reocclusion than angioplasty of subtotal stenoses. Whether this leads to adverse cardiovascular events is unknown. METHODS: The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Restenosis (MARCATOR) was a placebo-controlled trial with angiographic follow-up to determine the effect of the angiotensin-converting enzyme inhibitor cilazapril on the frequency of restenosis. In this trial, restenosis was defined as 1) angiographic reduction of minimal lumen diameter & or = 0.72 mm between angioplasty and the follow- and 2) & 50% diameter stenosis on the follow-up angiogram. We identified 139 patients with successful angioplasty of a coronary occlusion (Group 1) and compared the frequency of restenosis, reocclusion and adverse cardiovascular events with that in 1,295 patients with successful angioplasty of a subtotal stenosis (Group 2). RESULTS: Restenosis occurred in 36 patients with occluded arteries (29%) versus 264 with nonoccluded arteries (23%, p = 0.177) by definition 1 and in 62 patients with occluded arteries (49%) versus 478 with nonoccluded arteries (42%, p = 0.119) by definition 2. Occlusion was present in 24 Group 1 patients (19%) compared with 74 Group 2 patients (7%) (p & 0.001). During the 6 month follow-up period, two Group 1 patients (1.4%) and six Group 2 patients (0.5%) no Group 1 patients and 10 Group 2 patients (0.8%) developed severe cong nonfatal myocardial infarction occurred in 4 Group 1 patients (2.9%) and 31 Group 2 patients (2.4%); repeat coronary angioplasty or bypass surgery was performed in 29 Group 1 patients (21%) and 232 Group 2 patients (18%); and angina was present in 18 Group 1 and 163 Group 2 patients (13% for both). Eighty-six Group 1 patients (62%) and 853 Group 2 patients (66%) remained free of these adverse events during the 6-month follow-up period (p = 0.513). CONCLUSIONS: The frequency of restenosis was slightly but not significantly greater after successful angioplasty of an occluded artery than after angioplasty of a subtotal stenosis. Although reocclusion was more frequent, occurring in 19% of patients, the net clinical benefit of angioplasty in such patients was similar to that in patients with subtotal stenoses over the 6-month follow-up period.
)- subscription required
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
CitePeer Related Articles